Qualigen Therapeutics, Inc.
QLGN
$1.90
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.18% | 65.07% | 50.93% | 54.49% | 47.15% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -54.36% | -58.39% | -13.81% | -80.56% |
| Total Other Non-Cash Items | -77.74% | 85.43% | -88.83% | -1.45% | 158.80% |
| Change in Net Operating Assets | 55.28% | -369.87% | -83.41% | -58.82% | 28.50% |
| Cash from Operations | -102.83% | 59.98% | -293.60% | 49.65% | 70.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -527.95% | -129.57% | 823.14% | -- |
| Cash from Investing | -- | -527.95% | -129.57% | 823.14% | -- |
| Total Debt Issued | 57.89% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -353.64% | -354.55% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 57.89% | 3,794.00% | 854.39% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -270.84% | 114.18% | -94.14% | 100.84% | 88.45% |